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ABSTRACT
Objective: In a randomized trial, we sought to determine whether 2% clindamycin cream adminis-
tered intravaginally during labor to group B streptococcal-colonized pregnant women without risk
factors would decrease maternal and neonatal colonization.
Methods: The eligible women were randomized to receive either cream or no treatment. Two
hours after treatment or admission, the patients were tested with rectal and vaginal cultures. The
neonates of the study patients were also tested.
Results: Ofwomen randomized to cream, 5 of5 remained positive and 2 (33%) of their 6 neonates
were positive. Of4 randomized to no treatment, 3 (75%) remained positive and 1 (25%) of4 neonates
was positive.
Conclusions: Intravaginal 2% clindamycin cream was ineffective in reducing colonization with
group B streptococci. (C) 1996 Wiley-Liss, Inc.
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he recent recommendations for the prevention
of early-onset neonatal sepsis caused by group
B streptococci (GBS) have been limited to paren-
teral intrapartum antimicrobial prophylaxis for
women with clinical risk factors. 1,2 However, ap-
proximately 30% of the cases of early-onset GBS
sepsis occur in pregnancies without risk factors.
Prompted by recent work with hexachlorophene
douches in labor, we conducted a randomized trial
to evaluate 2% clindamycin cream as an intrapar-
turn topical approach in colonized women who did
not have clinical risk factors for neonatal sepsis.
We chose this cream because only 1-3% of GBS
strains are resistant to clindamycin, because it is
safe in pregnancy and because it is commercially
available.
MATERIALS AND METHODS
This protocol was approved by our institutional re-
view board. Under an existing clinical program of
universal screening and selective intrapartum pro-
phylaxis, patients with positive cultures at 26-28
weeks were identified by a research nurse after
their admissions in labor. The exclusions were age
younger than 18 years, allergy to clindamycin, re-
cent use of other antibiotics, and presence of a clini-
cal risk factor for GBS neonatal sepsis [anticipated
preterm birth <37 weeks gestation, preterm prema-
ture rupture of the membranes (PROM), PROM
> 12 h, and a clinical diagnosis ofchorioamnionitis].
The eligible patients were invited to participate in
a randomized trial of clindamycin cream (2%)vs. no
treatment. After an informed consent was obtained
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from the patient, a physician or research nurse col-
lected separate sterile swabs from the distal vagina
and the rectum. These were processed for GBS
using selective media and semiquantitative
technique.
With a computer-generated randomization, the
patients received either 5 ml of clindamycin cream
(2%) intravaginally through an applicator, with up
to 2 repeat doses, every 6 h in the absence of risk
factors, or no treatment in a ratio of 2:1. Two h after
each application of the cream or, in he patients
with no treatment, after the patient’s assignment,
we repeated the rectal and vaginal cultures. If a
patient developed a risk factor in labor, then we
planned to give parenteral antibiotics and eliminate
this patient from further consideration.
We obtained swabs from 4 neonatal sites (throat,
ear, umbilicus, and rectum) and processed these for
GBS, as above. The results were reported by the
site of culture.
Because of the lack of data on eradicating genital
GBS with clindamycin cream, some might suggest
that these experiments should be carried out only
in nonpregnant women. However, clindamycin
cream is safe in pregnancy. Indeed, it is the CDC
treatment of choice for bacterial vaginosis in the
first trimester. We were able to carry out a cost-
effective study by attaching it to an existing
protocol.
For sample size determination, we expected that
1) 65% of the women colonized at 26-28 weeks
would remain positive on admission, 2) the cream
would reduce both maternal and neonatal coloniza-
tion by 85-95%, and 3) GBS-positive cultures would
persist in 85-95% of untreated patients in labor. We
projected a sample size of 93 patients (62 receiving
clindamycin cream and 31 no treatment) using a
power of 0.8 and ot at 0.05.
RESULTS
From December 1, 1993, to August 31, 1994, 15
patients were enrolled; all were at ->37 weeks gesta-
tion. At this point, we were aware that the rate of
positive cultures after cream application was differ-
ent from expected. We then carried out an interim
analysis. Of the 15 participants, 5 (33%) were cul-
ture negative for GBS at admission. Four of these
received cream and no treatment. None of the
remaining 10 received parenteral antibiotics prior
to delivery. Of the 6 culture-positive women ran-
domized to the cream, did not have vaginal or
rectal cultures obtained. Five of 5 with vaginal cul-
tures and 3 of 5 with rectal cultures remained posi-
tive. One ofthese 5 women received multiple appli-
cations (3 doses). Her initial vaginal culture showed
4+ growth and the culture after the third dose was
still positive with + growth. The others delivered
within 6 h of their first dose. Two of their 6 neonates
(33%) were positive at 1 or more sites. One infant
was positive at all 4 sites (with 4+ growth) and
another had a positive umbilical culture (broth only)
but negative cultures at the other 3 sites. Of the 4
culture-positive women randomized to no treat-
ment, 3 (75%) remained positive vaginally and rec-
tally, and of 4 neonates (25%) was positive. This
infant was positive at all 4 sites (with 4+ growth).
These rates were not significantly different. At this
point, we calculated that the probability of finding
GBS eradication rate with the cream of approxi-
mately 0.9, with an observed rate of 0 of 5, is essen-
tially zero. Therefore, we terminated the study pre-
maturely.
DISCUSSION
We found that 2% clindamycin cream applied vagi-
nally in labor was ineffective in eradicating GBS
vaginal or rectal colonization 2 h after the applica-
tion. The rate of neonatal colonization after the
cream application was not different from the rate
after no treatment. Even though the numbers are
small, we found that the observed rates of GBS
eradication with clindamycin cream were far below
expectations and impractical for clinical use.
Considering the reasons for the ineffectiveness
of clindamycin cream, we may not have allowed
enough time. However, for many patients, if deliv-
ery does not occur in a few hours, risk factors may
develop. It is unlikely that the GBS isolates were
resistant to clindamycin, but the amniotic fluid or
fetus may have been colonizated before the applica-
tion of the cream.
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